The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
MPN Advances Day 2019 | The effect of vorinostat on methylation age in MPN patients
Mary Frances McMullin
• 15 Nov 2019
Mary Frances McMullin, MD, Queen’s University Belfast, Belfast, UK, discusses the effect of vorinostat on methylation age in myeloproliferative neoplasm (MPN) cell lines, and in patients with polycythemia vera (PV) and essential thrombocythemia (ET). The full paper can be read at https://www.ncbi.nlm.nih.gov/pubmed/31563618. This interview took place at the MPN Advances Day 2019 in London, UK.
